Day: October 11, 2021

Gaithersburg, MD, Oct. 11, 2021 (GLOBE NEWSWIRE) — mPhase Technologies, Inc. (OTC Pink: XDSL) (“mPhase” or the “Company”), a technology company developing the mPower 5G-enhanced electric vehicle (EV) charging network and consumer engagement platform, today announced that it has signed agreements with members of the Asian American Store Owners Association (AASOA) to add approximately 1,200 mPower locations in the State of Florida in Phase I of a statewide expansion, followed by additional locations (to be determined) in Phase II early next year. The mPower ecosystem is an integrated set of platform technologies consisting of consumer engagement software, EV charging, and 5G connectivity designed to create a beneficial link between consumers and retailers transitioning to an EV-centric future. All sites will initially receive the...

Cybersecurity leader to provide assessment and authorization for SCI and ISR networks and weapons platforms ASHBURN, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) — Telos® Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, announced today that it was awarded a $19.4 million expansion task order by the U.S. Air Force for the cyber risk management solution, Xacta. Under the contract, Telos will deliver assessment and authorization of sensitive compartmented information (SCI) and intelligence, surveillance and reconnaissance (ISR) networks and weapons platforms. “Our commitment to providing innovative technology to improve mission performance remains unwavering,” said John Wood, CEO and chairman, Telos. “We’re excited to expand on our longstanding...

VANCOUVER, British Columbia, Oct. 11, 2021 (GLOBE NEWSWIRE) — AgriFORCE Growing Systems Ltd. (“the Company”) (Nasdaq: AGRI), an innovative AgTech company focused on developing and acquiring agriculture IP that advances sustainable cultivation and processing for crops across multiple verticals, announced today that Ingo Mueller, CEO of AgriFORCE will be participating in two upcoming virtual investor conferences. Alliance Bernstein Digestible Disruption Conference Mr. Mueller will be presenting at the Bernstein Digestible Disruption Conference on Tuesday, October 12th at 11:00 a.m. EDT. Investors interested in attending the conference should contact their Bernstein sales representative. Maxim Group Global AgTech Virtual Conference Mr. Mueller will present at the Global AgTech Virtual Conference, presented by Maxim Group LLC and...

Currently Plans to File the 10-Q by November 9, 2021 ALLEN, Texas, Oct. 11, 2021 (GLOBE NEWSWIRE) — PFSweb, Inc. (NASDAQ: PFSW), a global commerce services company, announced that it has submitted a plan of compliance to the Nasdaq Stock Market relating to the delayed filing of its Form 10-Q for the period ended June 30, 2021. The filing of the Form 10-Q has been delayed due to the additional time and work needed to meet the SEC reporting and accounting requirements for its LiveArea divestiture, completed August 26, 2021, as a discontinued operation and other related financial reporting requirements associated with such divestiture. PFSweb has been working diligently over the past few months to complete the SEC reporting and accounting requirements. The company believes it is nearing completion and currently plans to be in a position...

  Paris, October 11, 2021,     Disclosure of Transactions in Own Shares   In accordance with the authorization given by the shareholders’ annual meeting on July 6, 2021 to trade on its own shares and pursuant to applicable law on share repurchase, Kering (LEI: 549300VGEJKB7SVUZR78) declares the following purchases of its own shares (FR0000121485) from October 4 to 8, 2021:Issuer’s name Issuer’s identifying code Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares Market (MIC code)KERING 549300VGEJKB7SVUZR78 04/10/2021 FR0000121485 19 500 621.3209 XPARKERING 549300VGEJKB7SVUZR78 05/10/2021 FR0000121485 19 500 620.0570 XPARKERING 549300VGEJKB7SVUZR78 06/10/2021 FR0000121485...

Integration of Plume’s SaaS experience platform with DZS Cloud and DZS Helix Edge Access portfolios creates DZS Xperience, a powerful solution for broadband service acceleration and monetizationDZS CloudIntegration of Plume’s SaaS experience platform with DZS Cloud and DZS Helix Edge Access portfolios creates DZS Xperience, a powerful solution for broadband service acceleration and monetization.PLANO, Texas, Oct. 11, 2021 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a global leader in broadband connectivity, mobile and optical transport, and software defined networking solutions, today announced a strategic partnership with personalized smart services pioneer Plume® to debut DZS Xperience, a new solution that sets the standard for intelligent, end-to-end broadband customer experience management and service delivery...

IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer. In this role, Ms. Hall will oversee nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management for all the company’s development programs. “We are happy to welcome Ashley to the Reneo leadership team,” said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. “Ashley is an experienced leader in the biopharmaceutical industry, with a track record of successfully bringing multiple novel drug products to market in the U.S.,...

YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials sponsored by Eucure Biopharma in Australia and China TRACON intends to initiate a Phase 1 trial of YH001 in combination with envafolimab in soft tissue sarcoma as well as to study YH001 in multiple other selected tumor types SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it has entered into a collaborative partnership...